Post Market Evaluation of Clinical Safety and Performance of the Fitbone Transport and Lengthening System

Orthofix

Status: Active, not recruiting

Conditions: Fractures, Open; Limb Defect; Fracture of Tibia; Fracture Nonunion; Limb Fracture; Limb Deformity; Fracture of Femur; Fractures, Closed; Limb Asymmetry; Fractures, Bone

Treatments: Device: Fitbone Transport and Lengthening System

Study type: Observational

Funder types: Industry

Identifiers

NCT06400732

CIP-FBBT-23

Details and patient eligibility

About

This is an open-label, prospective, observational, post-market, uncontrolled, multi-center study intended to evaluate the safety and clinical performance of the FITBONE Transport and Lengthening Nail when used according to the manufacturer's Instructions for Use. The FITBONE Transport & Lengthening Nail is a variant of the FITBONE TAA Nail, which has been commercially available in the US since 2017. The clinical performance and safety of the medical device have been assessed based on mechanical and biomechanical tests and clinical data obtained from scientific publications on equivalent products. This study intends to prospectively obtain clinical safety and performance data on the device, as used according to the manufacturer's Instructions for Use, in the real-world clinical setting.

The data obtained from this study will also be used to provide additional clinical evidence to support product registrations, as required by various regulatory bodies outside the US.

Eligible participants will have been selected by their physician to be treated with the FITBONE Transport and Lengthening System as part of treatment for their condition or injury. All procedures will be according to the physician's standard care practices. There are no study-specific procedures or requirements for participants in this study.

Full description

This prospective, observational clinical study intends to actively collect clinical data related to the use of the FITBONE Transport and Lengthening System in a representative number of users and patients, observed in the short (<1yr) and medium (approximately 1 and 2 years) term after implantation of the device.

Co-Primary Endpoints:

Primary Safety Endpoint: Percentage of unplanned reoperation and/or revision surgery. Instances of re-operation and/or revision as categorized as "planned" or "unplanned" by the surgeon.

Primary Performance Endpoint: Percentage of achievement of planned length. Length of the planned transport (and lengthening when applicable) vs the actual overall length of the segment at the time of nail extraction.

Secondary Endpoints:

• Bone Healing: Radiographic evidence of healing of 3 out of 4 cortices
• Consolidation Index: Time to achieve bone healing (days)/ achieved length (cm)
• Distraction Index: Time of distraction (days)/ achieved length (cm)
• Nail Reliability: Ratio between the number of successfully completed lengthening treatments and the number of implanted lengthening devices
• Nail Accuracy: Ratio between the achieved length and the planned length
• Time to achieve transport and lengthening
• Loss of Range of Motion at full consolidation: degrees from baseline
• Nail Extraction complications/failures
• Patient-reported outcome measures
• Mobility measures
• Adverse events

Safety Endpoint:

The percentage of cases in which unplanned reoperations and/or revision surgery occurred.

Enrollment: 30 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. ≥ 18 years old
2. Expressed willingness to participate in the study by signing and dating the informed consent form
3. Has a segmental bone defect, or limb length defect of at least 2 mm up to ≤ 120 mm, considered suitable for correction with an intramedullary lengthening nail, as confirmed by radiographs.

Exclusion criteria

1. Conditions that tend to retard healing such as blood supply limitations, peripheral vascular disease, or evidence of inadequate vascularity
2. Poor bone quality that would prevent adequate fixation of the device
3. Compromised capacity for healing
4. Metal allergies and sensitivities
5. Patients in which the implant would cross open, healthy epiphyseal growth plates
6. Insufficient intramedullary space which would lead to cortical weakening or vascular damage during implantation
7. Body weight of > 100 kg
8. No free access for proximal insertion of the intramedullary transport and lengthening nail (e.g., coxa valga)
9. No reliable exclusion of bone infection
10. Expected non-compliance, mentally ill patient or patient with clouded consciousness
11. Pregnancy
12. Pre-existing nerve palsies
13. Bone defect larger than 120 mm
14. Gustilo Open Fracture Classification Grade IIIB or IIIC

Trial design

30 participants in 1 patient group

Treatment Group

Description:

Participants treated for a limb defect with the Fitbone Transport and Lengthening System

Treatment:

Device: Fitbone Transport and Lengthening System